Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
GRAL vs GH: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
GH Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 7–3 Matrix Metrics)
GH Overall Winner
6-Pillar Tally: GRAL 1 – 4 GH (1 Tie)
Matrix Metrics: GRAL 3 – 7 GH
As of Nov 16, 2026, Guardant Health, Inc. (GH) is the stronger overall head-to-head candidate over GRAIL, Inc. (GRAL) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). GRAL carries a Unified Composite Score of 54.5/100 (HOLD) at $105.60 (1.1x Forward P/E, -332.0% operating margin), whereas GH carries 48.4/100 (HOLD) at $144.03 (N/M Forward P/E, -39.4% operating margin).
- Composite vs. Pillar Nuance: While GRAL currently prints a higher short-term Unified Composite Score (54.5/100 HOLD vs. GH 48.4/100 HOLD), GH captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-39.4% vs. -332.0% operating margin) and revenue trajectory (+36.1% vs. +3.7% YoY).
- Technical & Structure Timing Caution: GRAL is currently in a Breakdown options structure phase (RSI 37.7); meanwhile GH trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 34.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About GRAL vs GH
GRAL
GRAIL, Inc. Common Stock
$105.60
-8.88% 1D
Market Cap
$5.2B
TTM Revenue
$167M
Forward P/E
1.1x
Beta / 30D Vol
3.09β · 99% Vol
Unified Composite Score
54.5
HOLD
Tech 35.0
Fund 49.0
Flow 57.0
Mom 60.0
Weinstein Technical Phase
Neutral · Hold
GH
Head-to-Head Winner
Guardant Health, Inc. Common Stock
$144.03
-5.06% 1D
Market Cap
$20.5B
TTM Revenue
$1.28B
Forward P/E
N/M
Beta / 30D Vol
1.32β · 56% Vol
Unified Composite Score
48.4
HOLD
Tech 19.0
Fund 48.0
Flow 67.0
Mom 64.0
Weinstein Technical Phase
Neutral · Hold
6-Pillar Scorecard Institutional Category Breakdown (GRAL 1 – 4 GH)
1. Valuation Multiples
GRAL
Forward P/E
1.1x
N/M
Trailing P/E
1.1x
N/M
PEG Ratio
N/M
N/M
EV / Revenue
31.6x
16.6x
2. Growth & Scale
GH
Revenue Growth (YoY)
+3.7%
+36.1%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$167M
$1.28B
Market Cap
$5.2B
$20.5B
3. Profitability & Quality
GH
Gross Margin
46.7%
65.2%
Operating Margin
-332.0%
-39.4%
Net Profit Margin
-243.8%
-37.9%
Return on Equity (ROE)
-17.3%
0.0%
4. Balance Sheet & Cash Flow
GH
Cash Generation (TTM)
-$312M
-$232M
Cash Flow Margin
N/A
-18.2%
Net Cash / Leverage
$57M Net Debt (0.03x D/E)
$665M Net Debt
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
GH
Options Structure Phase
BREAKDOWN
CONSOLIDATION
Current IV / %ile
93.0% (53rd %ile)
72.2% (31st %ile)
Put/Call OI Skew
0.81x (Call-Skewed)
3.50x (Put-Skewed)
OBV Trend / Tech Phase
DISTRIBUTION · Neutral
DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Diagnostics & Research Operator
Diagnostics & Research Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: GRAL (3) vs GH (7)| Institutional Metric | GRAL | GH | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $5.2B | $20.5B | GH | |
| Trailing P/E Ratio | 1.1x | N/M | GRAL | |
| Forward P/E Ratio | 1.1x | N/M | GRAL | |
| Revenue Growth (YoY) | +3.7% | +36.1% | GH | |
| Operating Margin (TTM) | -332.0% | -39.4% | GH | |
| Net Profit Margin | -243.8% | -37.9% | GH | |
| Return on Equity (ROE) | -17.3% | 0.0% | GH | |
| 52-Week Range Position | 51% ($42–$166) | 60% ($75–$191) | GH | |
| Beta / 30D Volatility | 3.09β · 99% Vol | 1.32β · 56% Vol | GH | |
| Unified Institutional Score | 54.5 / 100 (HOLD) | 48.4 / 100 (HOLD) | GRAL | |
| Trailing 12M Revenue (USD) | $167M | $1.28B | Scale | |
| Gross Profit Margin (TTM) | 46.7% | 65.2% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 31.6x EV/Rev | N/M PEG · 16.6x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$312M ($57M Net Debt (0.03x D/E)) | -$232M ($665M Net Debt) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
GH +1.17 pp
3M Horizon
GRAL +61.87 pp
6M Horizon
GRAL +25.29 pp
1Y Horizon
GH +26.09 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | GRAL Revenue | GH Revenue | GRAL Op. Margin | GH Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | N/A | $90M | N/A | -102.5% | GH |
| FY2019 | N/A | $210M | N/A | -38.4% | GH |
| FY2020 | N/A | $290M | N/A | -88.9% | GH |
| FY2021 | N/A | $370M | N/A | -110.0% | GH |
| FY2022 | N/A | $450M | N/A | -121.1% | GH |
| FY2023 | $90M | $560M | -1627.6% | -100.1% | GH |
| FY2024 | $130M | $740M | -1743.0% | -60.0% | GH |
| FY2025 | $150M | $980M | -382.0% | -44.5% | GH |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
GRAL
BREAKDOWN
Current IV
93.0%
IV Percentile
53rd %ile
Put/Call OI Skew
0.81x (Call-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
DISTRIBUTION
Exact GRAL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
GH
CONSOLIDATION
Current IV
72.2%
IV Percentile
31st %ile
Put/Call OI Skew
3.50x (Put-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BEARISH
OBV Flow
DISTRIBUTION
Exact GH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
GRAL Moat Profile
Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
GH Moat Profile
Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ GRAL vs GH Key Questions & Quantitative Answers
As of Nov 16, 2026, Guardant Health, Inc. (GH) is the stronger overall head-to-head candidate over GRAIL, Inc. (GRAL) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). GRAL carries a Unified Composite Score of 54.5/100 (HOLD) at $105.60 (1.1x Forward P/E, -332.0% operating margin), whereas GH carries 48.4/100 (HOLD) at $144.03 (N/M Forward P/E, -39.4% operating margin). Composite vs. Pillar Nuance: While GRAL currently prints a higher short-term Unified Composite Score (54.5/100 HOLD vs. GH 48.4/100 HOLD), GH captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-39.4% vs. -332.0% operating margin) and revenue trajectory (+36.1% vs. +3.7% YoY). Technical & Structure Timing Caution: GRAL is currently in a Breakdown options structure phase (RSI 37.7); meanwhile GH trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 34.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
GH leads the Growth & Scale pillar: GRAL posts +3.7% YoY revenue growth and +0.0% YoY earnings growth on $167M TTM revenue (46.7% gross margin, -332.0% operating margin), compared with GH at +36.1% YoY revenue growth and +0.0% YoY earnings growth on $1.28B TTM revenue (65.2% gross margin, -39.4% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), GRAL cumulative revenue shifted +66.7% while GH shifted +988.9%. In operating R&D and SG&A reinvestment, GRAL deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for GH.
GRAL screens cheaper on headline valuation multiples. GRAL trades at 1.1x Forward P/E, 1.1x Trailing P/E, N/M PEG, and 31.6x EV/Revenue (unreported FCF margin), whereas GH trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 16.6x EV/Revenue (-18.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GRAL (-17.3% ROE) versus GH (0.0% ROE) capital efficiency.
In options market volatility and institutional positioning, GRAL carries 93.0% implied volatility (53rd %ile, Balanced (25th–60th %ile)), a 0.81x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (3.09β · 99% Vol realized risk). By comparison, GH carries 72.2% implied volatility (31st %ile, Balanced (25th–60th %ile)), a 3.50x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.32β · 56% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
GH vs GRAL · Reverse Pair
GRAL vs RVMD
· Sector Peer
GRAL vs WGS
· Sector Peer
GRAL vs NTRA
· Sector Peer
GH vs NTRA
· Sector Peer
GH vs TXG
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem